Gossamer Bio, Inc. (GOSS) Insider Trading Activity

NASDAQ$10.645+0.88 (9.01%)
Market Cap
$59.7M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
559 of 845
Rank in Industry
325 of 490

GOSS Insider Trading Activity

GOSS Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
–
Sells
$0
0
–

Related Transactions

About Gossamer Bio, Inc.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Insider Activity of Gossamer Bio, Inc.

Over the last 12 months, insiders at Gossamer Bio, Inc. have bought $0 and sold $0 worth of Gossamer Bio, Inc. stock.

On average, over the past 5 years, insiders at Gossamer Bio, Inc. have bought $442,157 and sold $284,358 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 26,050 shares for transaction amount of $50,016 was made by Milligan Sandra (director) on 2025‑08‑19.

List of Insider Buy and Sell Transactions, Gossamer Bio, Inc.

2025-08-19PurchaseMilligan Sandradirector
26,050
0.0115%
$1.92
$50,016
+8.85%
2024-06-24SaleAranda RichardChief Medical Officer
1,908
0.0007%
$0.66
$1,260
+16.58%
2024-06-21PurchaseHasnain FaheemPresident & CEO
372,000
0.2168%
$0.67
$250,282
+48.00%
2024-06-18PurchaseGiraudo BryanCOO/CFO
100,000
0.0512%
$0.59
$59,110
+77.24%
2024-06-17PurchaseSmith Robert Paul JRChief Commercial Officer
25,000
0.013%
$0.60
$15,050
+84.64%
2024-03-27SaleChristian WaageEVP, Tech Ops and Admin
6,430
0.0028%
$1.16
$7,430
-22.01%
2024-03-27SaleHasnain FaheemPresident & CEO
23,172
0.0101%
$1.16
$26,773
-22.01%
2024-03-27SaleGiraudo BryanCOO/CFO
6,430
0.0028%
$1.16
$7,431
-22.01%
2024-03-18SaleAranda RichardChief Medical Officer
4,018
0.0017%
$1.33
$5,342
-33.88%
2024-03-18SalePeterson CarynEVP, Regulatory Affairs
4,018
0.0017%
$1.33
$5,343
-33.88%
2023-11-15PurchaseMilligan Sandradirector
32,000
0.0139%
$0.79
$25,213
+11.06%
2023-11-13PurchaseGiraudo BryanCOO/CFO
200,000
0.0795%
$0.56
$112,880
+42.98%
2023-06-22SaleAranda RichardChief Medical Officer
1,814
0.0018%
$1.29
$2,340
-34.61%
2023-04-04PurchaseGiraudo BryanCOO/CFO
55,000
0.0583%
$1.02
$56,095
+3.96%
2023-03-16SaleAranda RichardChief Medical Officer
7,563
0.0083%
$1.10
$8,304
0.00%
2023-03-16SaleCarter LauraChief Scientific Officer
6,029
0.0066%
$1.10
$6,620
0.00%
2023-03-16SalePeterson CarynEVP, Regulatory Affairs
7,564
0.0083%
$1.10
$8,305
0.00%
2022-10-24SaleAranda RichardChief Medical Officer
4,757
0.0056%
$12.07
$57,431
-88.98%
2022-10-24SaleCarter LauraChief Scientific Officer
4,876
0.0058%
$12.07
$58,868
-88.98%
2022-10-24SalePeterson CarynEVP, Regulatory Affairs
4,757
0.0056%
$12.07
$57,431
-88.98%
Total: 63

Insider Historical Profitability

9.6%
Omega Fund V, L.P.10 percent owner
6553416
107.247%
$64.03M08
Hasnain FaheemPresident & CEO
5408073
88.5034%
$52.84M42
+8.78%
Gujrathi SheilaPresident & CEO
4048242
66.2497%
$39.55M10
<0.0001%
Christian WaageEVP, Tech Ops and Admin
585934
9.5888%
$5.72M43
<0.0001%
Giraudo BryanCOO/CFO
480010
7.8554%
$4.69M93
+10.16%
Salter-Cid LuisaChief Scientific Officer
206065
3.3723%
$2.01M03
Aranda RichardChief Medical Officer
196891
3.2221%
$1.92M08
Carter LauraChief Scientific Officer
76263
1.248%
$745,089.5116
Milligan Sandradirector
58050
0.95%
$567,148.5020
+9.96%
Peterson CarynEVP, Regulatory Affairs
49833
0.8155%
$486,868.4105
Smith Robert Paul JRChief Commercial Officer
25000
0.4091%
$244,250.0010
+84.64%
Cox Russell J.director
7200
0.1178%
$70,344.0010
+6.27%
Dupont JakobChief Medical Officer
0
0%
$002

Historical Insider Profitability vs. Competitors

$5,831,763
118
-33.78%
$65.45M
$9,405,928
107
12.61%
$59.38M
$17,525,882
60
5.22%
$61.7M
$103,288,323
51
4.78%
$54.8M
$19,705,388
47
86.26%
$61.87M
$909,129
37
42.19%
$66.67M
$24,478,755
37
-34.59%
$56.15M
$115,646,156
35
16.45%
$55.63M
$390,510
22
17.68%
$51M
$26,786,140
22
-18.62%
$68.65M
Gossamer Bio, Inc.
(GOSS)
$3,606,967
19
9.60%
$59.7M
$91,696,644
18
-4.72%
$49.09M
$17,594,514
16
-20.37%
$52.82M
$11,267,080
15
-22.36%
$65.33M
$31,682,927
12
-55.94%
$56.72M
$22,090,972
7
-3.49%
$59.98M
$106,599,960
6
-7.63%
$67.2M
$401,951
4
57.41%
$57.62M
$4,030
1
9.14%
$67.46M

GOSS Institutional Investors: Active Positions

Increased Positions121+76.58%31M+17.04%
Decreased Positions65-41.14%26M-14.33%
New Positions52New6MNew
Sold Out Positions16Sold Out5MSold Out
Total Postitions214+35.44%186M+2.71%

GOSS Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Nea Management Company, Llc$52,108.007.83%18.09M00%2025-09-30
Octagon Capital Advisors Lp$49,104.007.38%17.05M-1M-7.08%2025-09-30
Blackrock, Inc.$39,877.005.99%13.85M+2M+14.03%2025-09-30
Vanguard Group Inc$34,588.005.2%12.01M+598,981+5.25%2025-09-30
Arch Venture Management, Llc$23,201.003.49%8.06M00%2025-09-30
Samsara Biocapital, Llc$17,655.002.65%6.13M00%2025-09-30
Palo Alto Investors Lp$15,737.002.37%5.46M-274,664-4.79%2025-09-30
Siren, L.L.C.$15,002.002.26%5.21M00%2025-09-30
683 Capital Management, Llc$14,570.002.19%5.06M-1M-20.2%2025-09-30
Acadian Asset Management Llc$14,437.002.17%5.01M-2M-29.85%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.